29748 Federal Register / Vol. 87, No. 94 / Monday, May 16, 2022 / Notices 

CONTESTING RECORD PROCEDURES: 

Individuals wishing to contest or 

request an amendment to their records 

in this system of records must submit 

their request in writing to the FDIC 

FOIA & Privacy Act Group, 550 17th 

Street NW, Washington, DC 20429, or 

email efoia@fdic.gov. Requests must 

specify the information being contested, 

the reasons for contesting it, and the 

proposed amendment to such 

information in accordance with FDIC 

regulations at 12 CFR part 310. 

NOTIFICATION PROCEDURES: 

Individuals wishing to know whether 

this system contains information about 

them must submit their request in 

writing to the FDIC FOIA & Privacy Act 

Group, 550 17th Street NW, 

Washington, DC 20429, or email efoia@

fdic.gov. Requests must include full 

name, address, and verification of 

identity in accordance with FDIC 

regulations at 12 CFR part 310. 

EXEMPTIONS PROMULGATED FOR THE SYSTEM: 

None. 

HISTORY: 

None. 

Federal Deposit Insurance Corporation. 

Dated at Washington, DC, on May 6, 2022. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2022–10427 Filed 5–13–22; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than May 31, 2022. 

A. Federal Reserve Bank of Kansas 

City (Jeffrey Imgarten, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. The H.J. and Janet Podoll Living 

Trust dated June 24, 2002, and H.J. 

Podoll and Janet Podoll, as co-trustees, 

all of Lenexa, Kansas; to join the 

Clabaugh Family Group, a group acting 

in concert, to retain voting shares of 

CLC Enterprises, Inc., and thereby 

indirectly retain voting shares of 

Commercial Bank, both of Nelson, 

Nebraska. 

In addition, Todd A. Clabaugh, Elm 

Creek, Nebraska, and Travis Clabaugh, 

Sioux Center, Iowa; to join the Clabaugh 

Family Group to acquire additional 

voting shares CLC Enterprises, Inc., and 

thereby indirectly acquire additional 

voting shares of Commercial Bank. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–10494 Filed 5–13–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number CDC–2022–0066, NIOSH– 

346] 

Draft National Institute for 

Occupational Safety and Health 

(NIOSH) Healthcare Personal 

Protective Technology (PPT) Targets 

for 2020 to 2030; Request for Comment 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Request for information and 

comment. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) in the Centers for Disease 

Control and Prevention (CDC), an 

Operating Division of the Department of 

Health and Human Services (HHS), 

announces the availability of a draft 

document entitled DRAFT NIOSH 

Healthcare Personal Protective 

Technology (PPT) Targets for 2020 to 

2030 (Draft PPT Targets) now available 

for public comment. 

DATES: Electronic or written comments 

must be received by July 15, 2022. 

ADDRESSES: You may submit comments, 

identified by CDC–2022–0066 and 

docket number NIOSH–346, by either of 

the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: National Institute for 

Occupational Safety and Health, NIOSH 

Docket Office, 1090 Tusculum Avenue, 

MS C–34, Cincinnati, Ohio 45226–1998. 

Instructions: All information received 

in response to this notice must include 

the agency name and docket number 

(CDC–2022–0066; NIOSH–346). All 

relevant comments, including any 

personal information provided, will be 

posted without change to https://

www.regulations.gov. Do not submit 

comments by email. CDC does not 

accept comments by email. For access to 

the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Susan M. Moore, NIOSH NPPTL, 

Building 141, 626 Cochrans Mill Road, 

Pittsburgh, PA 15236; Telephone: 412– 

386–6111. 

SUPPLEMENTARY INFORMATION: Reflecting 

on the nation’s past decade of 

experiences with infectious diseases 

(e.g., influenza, Ebola virus disease, and 

coronavirus disease) and non-infectious 

hazards (e.g., antineoplastic and other 

hazardous drugs), the National Institute 

for Occupational Safety and Health 

(NIOSH) recognizes a growing need for 

its unique capabilities related to PPT 

research, development, performance 

standards and test methods, and 

conformity assessment. In response to 

this growing need, NIOSH established 

DRAFT Healthcare PPT Targets for 2020 

to 2030. 

Background: The health and welfare 

of 18 million U.S. healthcare personnel 

(HCP) is an important priority for 

NIOSH and CDC. NIOSH’s mission is to 

protect the U.S. workforce from injury 

and illness via scientific research, 

practice interventions, and collaborative 

partnerships. While infection 

prevention and control efforts favor the 

role of engineering and administrative 

measures over PPT, PPT plays an 

important role in preventing 

transmission of infectious diseases. PPT 

includes personal protective equipment 

(PPE) worn by individuals (e.g., 

respirators; protective clothing; gloves, 

eye, fall and hearing protection; and 

hard hats) and technical methods (e.g., 


JSPEARS on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 94 / Monday, May 16, 2022 / Notices 29749 

fit testing methods), processes, 

techniques, tools, and materials that 

support the development and use of PPE 

worn by individuals. 

In 2006, the NIOSH Personal 

Protective Technology Laboratory 

(NPPTL) began an initiative to develop 

and execute a comprehensive strategic 

approach to HCP protection. The 

resulting NIOSH Healthcare PPT Action 

Plan focused resources on and raised 

awareness about the PPT needs of HCP 

during a potential influenza pandemic. 

NIOSH undertook a research agenda to 

advance clinical practices, drive 

performance standards development, 

and inform regulation. In addition, 

NIOSH carried out an information 

dissemination program to apprise 

healthcare organizations and HCP about 

the roles and importance of PPE in 

protecting themselves. The Action Plan 

has been updated several times since its 

inception. The most recent plan (2013– 

18) focused on PPE used to reduce 

exposures to viral respiratory pathogens, 

including the influenza virus. 

Reflecting on the nation’s past decade 

of experiences with infectious diseases 

(e.g., influenza, Ebola, and coronavirus) 

and non-infectious hazards (e.g., 

antineoplastic and other hazardous 

drugs), NIOSH recognizes a growing 

need for its unique capabilities related 

to PPT research, development, 

performance standards and test 

methods, and conformity assessment. 

To respond to this growing need, 

NIOSH developed DRAFT NIOSH 

Healthcare PPT Targets for 2020 to 2030 

(Draft PPT Targets), which have 

informed NIOSH’s PPT efforts since 

2020. The public health response to the 

COVID–19 pandemic has delayed 

NIOSH’s efforts to obtain public input 

on the PPT Targets; NIOSH will finalize 

the PPT Targets after receipt of the 

requested public input. To view the 

Draft PPT Targets, please visit https://

www.cdc.gov/niosh/npptl/ 

hospresptoolkit/ 

DraftHealthcarePPT.html. 

Information Needs: Additional data 

and information are needed to assist 

with finalizing the Draft PPT Targets. 

Interested persons or organizations are 

invited to submit applicable materials, 

including published and unpublished 

reports and research findings, that 

NIOSH may consider to: 

• Align its activities with other 

national efforts related to PPT; 

• Coordinate and prioritize NIOSH 

targets with complementary efforts by 

other entities; 

• Explore opportunities to collaborate 

with other entities; 

• Determine the level of effort needed 

to address specific targets; 

• Explore additional or alternative 

technical approaches; and 

• Explore additional knowledge gaps 

requiring support until 2030. 

Disclaimer: This notice is intended for 

planning purposes; it does not 

constitute a formal announcement for 

comprehensive applications. In 

accordance with Federal Acquisition 

Regulation 48 CFR 15.201(e), responses 

to this notice are not offers and cannot 

be accepted by the Government to form 

a binding award. NIOSH will not 

provide reimbursement for costs 

incurred in commenting on this notice. 

NIOSH will not respond to individual 

public comments or publish publicly a 

compendium of responses. An 

informational submission in response to 

this notice does not create any 

commitment by or on behalf of CDC or 

HHS to develop or pursue any program 

or ideas discussed. 

John J. Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2022–10413 Filed 5–13–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2019–N–2854] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Premarket 

Tobacco Product Applications and 

Recordkeeping Requirements 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on ‘‘Premarket 

Tobacco Product Applications and 

Recordkeeping Requirements.’’ 

DATES: Submit either electronic or 

written comments on the collection of 

information by July 15, 2022. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before July 15, 2022. 

The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of July 15, 2022. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2019–N–2854 for ‘‘Premarket Tobacco 

Product Applications and 

Recordkeeping Requirements.’’ 

Received comments, those filed in a 


JSPEARS on DSK121TN23PROD with NOTICES1